PIK3CA and proliferative glomerulonephritis: What remains unknown are the precise mechanisms of p110α-mediated cell cycle reinitiation, the contributions of AKT isoforms to podocyte proliferation in human disease, and the potential therapeutic utility of targeting other PI3K pathway intermediates for the treatment of proliferative glomerulonephritis.